Elanco Animal Health Incorporated Stock-Based Compensation
Elanco Animal Health Incorporated (ELAN) reported Stock-Based Compensation of $41.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-05
- Elanco Animal Health Incorporated share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $20.00M, a 0.00% change year-over-year.
- Elanco Animal Health Incorporated share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $21.00M, a 40.00% increase year-over-year.
- Elanco Animal Health Incorporated share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $16.00M, a 6.67% increase year-over-year.
- Elanco Animal Health Incorporated share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $17.00M, a 13.33% increase year-over-year.
- Elanco Animal Health Incorporated share-based payment arrangement, noncash expense for fiscal 2025 was $68.00M, a 23.64% increase from fiscal 2024.
- Elanco Animal Health Incorporated share-based payment arrangement, noncash expense for fiscal 2024 was $55.00M, a 19.57% increase from fiscal 2023.
- Elanco Animal Health Incorporated share-based payment arrangement, noncash expense for fiscal 2023 was $46.00M, a 22.03% decline from fiscal 2022.
- Elanco Animal Health Incorporated share-based payment arrangement, noncash expense for fiscal 2022 was $59.00M, a 10.61% decline from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 3 month as first filed | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 9 month as first filed | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $41.00M 10-Q · filed 2026-08-05 | $57.00M derived: sum of 3 quarters · filed 2026-08-05 | $74.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $21.00M 10-Q · filed 2026-05-06 | $37.00M derived: sum of 2 quarters · filed 2026-05-06 | $54.00M derived: sum of 3 quarters · filed 2026-05-06 | $74.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $33.00M derived: sum of 2 quarters · filed 2026-02-24 | $53.00M derived: sum of 3 quarters · filed 2026-08-05 | $68.00M 10-K · filed 2026-02-24 | ||||
| 2025-09-30 | $17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $37.00M derived: sum of 2 quarters · filed 2026-08-05 | $52.00M 10-Q · filed 2025-11-05 | $67.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-06-30 | $20.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $35.00M 10-Q · filed 2026-08-05 | $50.00M derived: sum of 3 quarters · filed 2026-08-05 | $65.00M derived: sum of 4 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $15.00M 10-Q · filed 2026-05-06 | $30.00M derived: sum of 2 quarters · filed 2026-05-06 | $45.00M derived: sum of 3 quarters · filed 2026-05-06 | $59.00M derived: sum of 4 quarters · filed 2026-05-06 | ||||
| 2024-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $30.00M derived: sum of 2 quarters · filed 2026-02-24 | $44.00M derived: sum of 3 quarters · filed 2026-02-24 | $55.00M 10-K · filed 2026-02-24 | ||||
| 2024-09-30 | $15.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $29.00M derived: sum of 2 quarters · filed 2025-11-05 | $40.00M 10-Q · filed 2025-11-05 | $55.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-06-30 | $14.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $25.00M 10-Q · filed 2025-08-07 | $40.00M derived: sum of 3 quarters · filed 2026-02-24 | $50.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2024-03-31 | $11.00M 10-Q · filed 2025-05-07 | $26.00M derived: sum of 2 quarters · filed 2026-02-24 | $36.00M derived: sum of 3 quarters · filed 2026-02-24 | $45.00M derived: sum of 4 quarters · filed 2026-02-24 | ||||
| 2023-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $25.00M derived: sum of 2 quarters · filed 2026-02-24 | $34.00M derived: sum of 3 quarters · filed 2026-02-24 | $46.00M 10-K · filed 2026-02-24 | ||||
| 2023-09-30 | $10.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $19.00M derived: sum of 2 quarters · filed 2024-11-07 | $31.00M 10-Q · filed 2024-11-07 | $46.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-06-30 | $9.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $21.00M 10-Q · filed 2024-08-08 | $36.00M derived: sum of 3 quarters · filed 2025-02-25 | $49.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2023-03-31 | $12.00M 10-Q · filed 2024-05-08 | $27.00M derived: sum of 2 quarters · filed 2025-02-25 | $40.00M derived: sum of 3 quarters · filed 2025-02-25 | $57.00M derived: sum of 4 quarters · filed 2025-02-25 | ||||
| 2022-12-31 | $15.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $28.00M derived: sum of 2 quarters · filed 2025-02-25 | $45.00M derived: sum of 3 quarters · filed 2025-02-25 | $59.00M 10-K · filed 2025-02-25 | ||||
| 2022-09-30 | $13.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $30.00M derived: sum of 2 quarters · filed 2023-11-07 | $44.00M 10-Q · filed 2023-11-07 | $62.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $17.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $31.00M 10-Q · filed 2023-08-07 | $49.00M derived: sum of 3 quarters · filed 2024-02-26 | $66.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $14.00M 10-Q · filed 2023-05-09 | $32.00M derived: sum of 2 quarters · filed 2024-02-26 | $49.00M derived: sum of 3 quarters · filed 2024-02-26 | $65.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $18.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $35.00M derived: sum of 2 quarters · filed 2024-02-26 | $51.00M derived: sum of 3 quarters · filed 2024-02-26 | $66.00M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $17.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $33.00M derived: sum of 2 quarters · filed 2022-11-08 | $48.00M 10-Q · filed 2022-11-08 | $64.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $16.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $31.00M 10-Q · filed 2022-08-08 | $47.00M derived: sum of 3 quarters · filed 2023-03-01 | $59.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $15.00M 10-Q · filed 2022-05-09 | $31.00M derived: sum of 2 quarters · filed 2023-03-01 | $43.00M derived: sum of 3 quarters · filed 2023-03-01 | $51.00M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | $16.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $28.00M derived: sum of 2 quarters · filed 2023-03-01 | $36.00M derived: sum of 3 quarters · filed 2023-03-01 | $47.00M 10-K · filed 2023-03-01 | $47.70M 10-K · filed 2021-03-01 | |||
| 2020-09-30 | $12.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $20.00M derived: sum of 2 quarters · filed 2021-11-05 | $31.00M 10-Q · filed 2021-11-05 | $31.10M 10-Q · filed 2020-11-06 | $43.30M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | $8.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $19.00M 10-Q · filed 2021-08-09 | $19.40M 10-Q · filed 2020-07-30 | $31.30M derived: sum of 3 quarters · filed 2022-02-28 | $46.10M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | $11.00M 10-Q · filed 2021-05-07 | $11.10M 10-Q · filed 2020-05-07 | $23.30M derived: sum of 2 quarters · filed 2022-02-28 | $38.10M derived: sum of 3 quarters · filed 2022-02-28 | $52.30M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $12.30M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $27.10M derived: sum of 2 quarters · filed 2022-02-28 | $41.30M derived: sum of 3 quarters · filed 2022-02-28 | $49.00M 10-K · filed 2022-02-28 | $49.40M 10-K · filed 2020-02-28 | |||
| 2019-09-30 | $14.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $29.00M derived: sum of 2 quarters · filed 2020-11-06 | $36.70M 10-Q · filed 2020-11-06 | $42.50M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-06-30 | $14.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $21.90M 10-Q · filed 2020-07-30 | $27.70M derived: sum of 3 quarters · filed 2021-03-01 | $34.60M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2019-03-31 | $7.70M 10-Q · filed 2020-05-07 | $13.50M derived: sum of 2 quarters · filed 2021-03-01 | $20.40M derived: sum of 3 quarters · filed 2021-03-01 | $26.80M derived: sum of 4 quarters · filed 2021-03-01 | ||||
| 2018-12-31 | $5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $12.70M derived: sum of 2 quarters · filed 2021-03-01 | $19.10M derived: sum of 3 quarters · filed 2021-03-01 | $26.00M 10-K · filed 2021-03-01 | ||||
| 2018-09-30 | $6.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $13.30M derived: sum of 2 quarters · filed 2019-11-08 | $20.20M 10-Q · filed 2019-11-08 | $26.50M derived: sum of 4 quarters · filed 2020-02-28 | ||||
| 2018-06-30 | $6.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-13 | $13.30M 10-Q · filed 2019-08-13 | $19.60M derived: sum of 3 quarters · filed 2020-02-28 | |||||
| 2018-03-31 | $6.90M 10-Q · filed 2019-05-14 | $13.20M derived: sum of 2 quarters · filed 2020-02-28 | ||||||
| 2017-12-31 | $6.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-28 | $25.00M 10-K · filed 2020-02-28 | ||||||
| 2017-09-30 | $18.70M 10-Q · filed 2018-11-08 | |||||||
| 2016-12-31 | $20.40M 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |